Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2

Takeshi Arashiro1,2,3,4, Yuzo Arima1, Jin Kuramochi5,6

  • 1Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.

PubMed